

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50120/008001
	Serial No.	10/585,772
	Applicant	Young et al.
	Filing Date	November 13, 2007
	Group	1635
	IDS Filed	May 25, 2010

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	2003/0175950	September 18, 2003	McSwiggen
	2004/0006035	January 8, 2004	Macejak et al.
	2004/0068763	April 8, 2004	Hopkins et al.
	2005/0255487	November 17, 2005	Khvorova et al.
	2006/0241070	October 26, 2006	Wright
	2008/0255085	October 16, 2008	Young et al.
	12/691,664	N/A	
	12/700,563	N/A	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	WO 03/099298	December 4, 2003	WIPO	
	WO 04/070033	August 19, 2004	WIPO	
	WO 05/065719	July 21, 2005	WIPO	
	WO 06/017932	February 23, 2006	WIPO	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Agrawal and Kandimalla, Antisense and/or immunostimulatory oligonucleotide therapeutics, Curr Cancer Drug Targets. 2001 Nov;1(3):197-209.
	Björklund et al., Structure and promoter characterization of the gene encoding the large subunit (R1 protein) of mouse ribonucleotide reductase, Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11322-6.
	Duxbury et al., Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer, Surgery. 2004 Aug;136(2):261-9.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	November 13, 2007
		Group	1635
		IDS Filed	May 25, 2010
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	GenBank Entry ay032750, "Homo sapiens ribonucleotide reductase M2 subunit (RRM2) gene, complete cds." (May 12, 2001), National Center for Biotechnology Information, Bethesda, MD.
	GenBank Entry BC001886, "Homo sapiens ribonucleotide reductase M2 polypeptide, mRNA (cDNA clone MGC:1551 IMAGE:3528619), complete cds." (January 29, 2001), National Center for Biotechnology Information, Bethesda, MD.
	International Search Report for PCT/CA2004/00175, mailed May 7, 2004.
	International Search Report for PCT/CA2005/00040, mailed June 7, 2005.
	International Search Report for PCT/CA2005/001258, mailed January 3, 2006.
	Lee et al., GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors, Cancer Res. 2003 Jun 1;63(11):2802-11.
	Lepoivre et al., Alterations of ribonucleotide reductase activity following induction of the nitrite-generating pathway in adenocarcinoma cells, J Biol Chem. 1990 Aug 25;265(24):14143-9.
	Lin et al., Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors, J Biol Chem. 2004 Jun 25;279(26):27030-8. Epub 2004 Apr 19.
	Mader et al., Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitro, Biochem Pharmacol. 1997 Dec 1;54(11):1233-42.
	Office Action (U.S. Application No. 10/545,152), mailed September 21, 2009.
	Office Action (U.S. Application No. 11/573,879), mailed September 29, 2008.
	Office Action (U.S. Application No. 11/573,879), mailed February 13, 2009.
	Office Action (U.S. Application No. 11/573,879), mailed November 5, 2009.
	Orr, Technology evaluation: leukemia therapy, University of Pennsylvania, Curr Opin Mol Ther. 1999 Jun;1(3):399-403.
	Pavloff et al., Sequence analysis of the large and small subunits of human ribonucleotide reductase, DNA Seq. 1992;2(4):227-34.
	Vose et al., Update on epidemiology and therapeutics for non-Hodgkin's lymphoma, Hematology Am Soc Hematol Educ Program. 2002:241-62.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	